Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings, and welcome to the QBioPharma fourth quarter and full year 2022 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone were to require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Dan Passeri, Chief Executive Officer. Please go ahead. Yeah, thank you, and good afternoon, everyone. As a reminder, this conference will be recorded and available on our website for the next 30 days. Also, as a reminder, those listening in, just be aware of the webcast. You need to advance the slides as you are listening, and we'll notify you which slide we're on at a given time. Joining me on today's call is Dr. Matteo Levesetti, our Chief Medical Officer, Dr. Ken Pienta, now in the role as Clinical Advisory Cue, Dr. Anish Suri, our President and Chief Scientific Officer, and Kerry Millar, our Chief Financial Officer. Also joining us briefly on today's call is Dr. Sarah Pei, Surgical Oncologist and Director of Translational Head and Neck Cancer Research at the Mass General Hospital. She's an investigator on our ongoing trial with Q101. We'll provide a brief perspective of clinical observations to date. In addition to Dr. Pienta, Dr. Pei has also recently become a clinical advisor to QBioPharma, helping to define our clinical strategies going forward. As shown here on slide two, this presentation and overview may contain some forward-looking statements, and any forward-looking statements made during this call represents the company's views as of today, March 21st, 2023. On the next slide, please, you'll see our agenda. for today...